CardiologyOnline.net :: Cardiology

Cardiology Online, Cardiology Xagena, Cardiology Newsletter, Cardiology News, Updates in cardiology, Aggiornamento in Medicina, Cardiovascular Drugs :: Updates, Cancer Drugs :: Updates,

Brilinta Antiplatelet agents: Brilinta first to show reduction in …	Clinical outcomes according to … Clinical outcomes according to QRS duration and morphology …
Cordarone Atrial fibrillation: Betapace less effient than Cordarone for …	Lower dose beta-blocker … Lower dose beta-blocker therapy is … therapy will be associated …
Crestor Crestor may reverse atherosclerosis in patients with …	Angiox Myocardial infarction: Heparin rather than Bivalirudin after …
Angiomax Angiomax alone reduces a significant number of major …	Acute myocardial infarction … Acute myocardial infarction: Cyclosporine, an …
Patients with ST-segment … Patients with ST-segment elevation myocardial infarction …	Treatment of heart failure: the … Treatment of heart failure: the path to Entresto, an … to an …
Altri risultati in cardiologyonline.net »

Cardiology – CardiologyOnline.net

Cardiology, Cardiology News, Cardiology Newsletter, Newsletter Cardiology, Xagena Medical News, Arrhythmia Newsletter,Drugs in Cardiology Newsletter, Cardiovascular Drugs Newsletter, STEMI Newsletter, NSTEMI Newsletter, PCI Newsletter, UTIC Newsletter, Heart Failure Newsletter, Cardiovascular Drugs Newsletter,

Cordarone Atrial fibrillation: Betapace less effient than Cordarone for …	Direct factor Xa inhibitors Direct factor Xa inhibitors: Edoxaban compared with …
Non-valvular atrial fibrillation … Non-valvular atrial fibrillation: Dabigatran, a safe and …	ENGAGE AF-TIMI 48 trial … ENGAGE AF-TIMI 48 trial: transition of patients from …
Antiarrhythmic drugs Antiarrhythmic drugs: Dronedarone associated with …	Bivalirudin Myocardial infarction: Heparin rather than Bivalirudin after …
Dual antiplatelet therapy PRODIGY study: appropriate duration of dual antiplatelet …	Post-infarction patients: Insulin … Post-infarction patients: Insulin resistance predicts the risk for …
Diuretics Thiazide-type diuretics remain the drugs of choice for initial …	Angiomax Angiomax alone reduces a significant number of major …
Altri risultati in cardiologyonline.net »

Cardiology Updates

Aprile 22, 2018

Medicina

Cardiology – CardiologyOnline.net

Cardiology, Cardiology News, Cardiology Newsletter, Newsletter Cardiology, Xagena Medical News, Arrhythmia Newsletter, Drugs in Cardiology Newsletter, Cardiovascular Drugs Newsletter, STEMI Newsletter, NSTEMI Newsletter, PCI Newsletter, UTIC Newsletter, Heart Failure Newsletter, Cardiovascular Drugs Newsletter,

Cordarone Atrial fibrillation: Betapace less effient than Cordarone for …	Direct factor Xa inhibitors Direct factor Xa inhibitors: Edoxaban compared with …
Non-valvular atrial fibrillation … Non-valvular atrial fibrillation: Dabigatran, a safe and …	ENGAGE AF-TIMI 48 trial … ENGAGE AF-TIMI 48 trial: transition of patients from …
Antiarrhythmic drugs Antiarrhythmic drugs: Dronedarone associated with …	Bivalirudin Myocardial infarction: Heparin rather than Bivalirudin after …
Dual antiplatelet therapy PRODIGY study: appropriate duration of dual antiplatelet …	Post-infarction patients: Insulin … Post-infarction patients: Insulin resistance predicts the risk for …
Diuretics Thiazide-type diuretics remain the drugs of choice for initial …	Angiomax Angiomax alone reduces a significant number of major …
Altri risultati in cardiologyonline.net »

Cardiology News by Xagena

Aprile 19, 2018Aprile 19, 2018

Medicina

Updates in Cardiology

FDA ( Food and Drug Administration )

FDA: no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication Olmesartan in patients with diabetes

The FDA ( Food and Drug Administration ) has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication Olmesart …

News

Patients with bicuspid aortic valve without Marfan syndrome: identification of fibrillin 1 gene mutations

Bicuspid aortic valve ( BAV ) is the most frequent congenital heart disease with frequent involvement in thoracic aortic dilatation, aneurysm and dissection. Although BAV and Marfan syndrome ( MFS ) share some clinical features, and some MFS … more

Angiotensin receptor neprilysin inhibitors: independence of the blood pressure lowering effect and efficacy of the LCZ696, in patients with heart failure with preserved ejection fraction

The first in class angiotensin receptor neprilysin inhibitor ( ARNI ), LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ), reduce left atrial size and improve New York Heart Association ( NYHA ) class in … more

Anticoagulation with Warfarin offers a net benefit in patients with atrial fibrillation and renal failure

A study has evaluated if Warfarin provides net benefit in patients with atrial fibrillation and renal failure. The data in this retrospective study of 283,969 patients with atrial fibrillation were obtained by analysis of health care databases in … more